Overview
BRII-B (2137)
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The...
- Open
- 1.035
- High
- 1.065
- Low
- 0.970
- Prev. Close
- 1.065
- Volume
- 1.73M
- Turnover
- 1.75M
- Avg Price
- 1.013
- Bid/Ask Ratio
- 21.21%
- Amplitude
- 8.92%
- 52wk High
- 1.880
- Volume Ratio
- 4.47
- Turnover Ratio
- 0.24%
- 52wk Low
- 0.815
- HK Mkt Cap
- 733.63M
- Market CapHKD
- 733.63M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.280
- EPSDynamic
- -0.322
- EPSStatic
- --
- BVPS
- 3.55
- P/B
- 0.29
- HK Shares
- 719.25M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 719.25M
- Min lot size
- 500
- Currency
- HKD
BRII-B Analyst Rating
View moreForecast & Rating
Mar 25, 2026- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Brii Biosciences (2137.HK) failed to hold onto gains after Phase 2b ENRICH data showed 32.4% HBsAg loss at 24 weeks, trading at HKD1.050, down 1.4% from the previous close of HKD1.065; it opened at the HKD1.065 high, fell to HKD0.970 in the afternoon session and rebounded to HKD1.025 late in the day, leaving a wide HKD0.970-HKD1.065 range on about 1.71 million shares and HKD1.73 million turnover. The rebound trimmed the intraday decline, but the stock remained below the previous close. AASLD 2026 late-breaking data supported the BRII-179-based priming and enrichment strategy, yet latest news showed the shares fell as much as 6% intraday. The company has repeatedly disclosed share buybacks, while Q2 2026 net loss was HKD58.08 million, narrowing 28.41% year on year, and EPS was -HKD0.0791, improving 29.47%; operating loss was HKD87.15 million, narrowing 8.87%. At HKD1.050, the stock is 44.74% below its 52-week high of HKD1.9, down 26.06% year to date, but above its MA20 of 0.987 and MA60 of 0.929, with a PB of 0.300 and market capitalization of HKD755 million. Though the hepatitis B data and buybacks have not yet led to sustained volume expansion.
- Nov, 4
The stock opened at HK$0.980, slipped to HK$0.970 at 11:58, then climbed through the afternoon to a HK$1.020 high at 15:20 and closed at HK$1.010, roughly 3% above the morning open, on 1.017 million shares and about HK$1.02 million turnover at an average of HK$1.0024, with volume following the upward drift. The bid was underpinned by a near-daily buyback programme: 302,500 shares repurchased for HK$302,100 on 3 November, 283,000 shares on 30 October and 255,000 shares on 28 October, with disclosures on almost every trading day since late October, plus an equity disclosure filing on 2 November. On positioning, the stock is still down 27.82% year to date and 46.05% below its 52-week high of HK$1.90, yet it now sits above the MA20 of HK$0.912 and MA60 of HK$0.920 and 25.77% above the 52-week low of HK$0.815; market value is HK$738.9 million, P/B 0.29 and P/E negative. Though turnover of roughly HK$1.02 million and a 0.14% turnover rate point to thin liquidity.
- Nov, 3
Brii Biosciences (2137.HK) spiked and faded: it opened at HK$1.080, then buying dried up, the shares slid to HK$0.975 by 11:07 BJ and settled at HK$0.980, down 2.49% from the prior close of HK$1.005 on a thin 0.11% turnover rate. Buybacks have run almost daily since mid-October, including 283,000 shares for HK$274,400 on 30 October and 62,500 shares for HK$62,300 on 2 November, yet they have not cleared selling pressure around the HK$1 line. Fundamentals remain pre-revenue: Q2 2026 revenue was blank while the net loss of HK$58.1 million narrowed 28.41% year on year and loss per share of HK$0.0791 improved 29.47%; the BRiSC siRNA platform launched in October has yet to generate income. The stock sits above its MA20 of 0.906 and MA60 of 0.920 but is down 30.99% year to date and 48.42% below the 52-week high of HK$1.9. It is nonetheless 20.25% above the 14 October low of HK$0.815.
- Oct, 26
BRII Biosciences (2137.HK) opened low and closed high, dipping to HK$0.880 early before peaking at HK$0.955 by 11:55 BJ and settling at HK$0.945, up about 5.6% on 1.541 million shares worth HK$1.437 million. The bid followed a run of buybacks (78,000 shares on Oct 23, 54,500 on Oct 22) and the BRiSC dual-targeting siRNA platform launched in October. Fundamentals remain in loss-narrowing mode: Q2 2026 EPS was -HK$0.0791 with a net loss of HK$58.08 million, improved about 28% year on year. Price positioning is still weak, down 33.45% YTD and 52.51% below the 52-week high of HK$1.99, though the shares sit above MA20 (0.874) and MA60 (0.916). However, with PB at 0.270 and market cap of HK$681.9 million, buybacks of only tens of thousands of Hong Kong dollars each offer limited actual support.
- Oct, 23
Brii Biosciences reversed early weakness to close at the session high: after touching 0.855 at 11:28 BJ, it ran to 0.915 at 15:59 BJ and settled at 0.895, up 2.87% from 0.870 on about 743k shares. The move was anchored by steady buybacks — 54,500 shares for HK$49,000 on October 22 and 110,000 shares for HK$93,000 on October 13 — which support a thinly traded float, alongside the launch of the BRiSC™ dual-targeting siRNA platform. Fundamentals remain loss-making but improving: Q2 2026 EPS of -HK$0.0791 narrowed 29.47% yoy and the HK$58.1m net loss narrowed 28.41%, with PB at 0.25x. The price is back above its 20-day MA of 0.872 yet still under the 60-day MA of 0.916, down 36.97% YTD and 55.03% below the 52-week high of 1.99, though it sits 9.82% above the October 14 low of 0.815. While no revenue has been recorded and a profit inflection is not yet visible, buyback size remains small versus the HK$645.9m market cap.
News
Market Movers · BRII drops 6% in Hong Kong trading
PUBT · Brii Biosciences Files Next Day Disclosure Return to HKEX Announcing Share Buyback
TechNode · SEA AI funding rises 121 percent to $4.2 billion in 9M 2026 – Tracxn
PUBT · Brii Biosciences Files Next Day Disclosure Return With HKEX Announcing Share Buyback
PUBT · Brii Biosciences Reports Share Buyback in HKEX Next-Day Disclosure Return
Tip Ranks · Brii Reports Encouraging Phase 2b Hepatitis B Results
